Authors
Remko Van Leeuwen, Christine Katlama, Robert L Murphy, Kathleen Squires, José Gatell, Andrej Horban, Bonaventura Clotet, Shlomo Staszewski, Arne Van Eeden, Nathan Clumeck, Mauro Moroni, Andrew T Pavia, Reinhold E Schmidt, Juan Gonzalez-Lahoz, Julio Montaner, Francisco Antunes, Robert Gulick, Dénes Bánhegyi, Marc Van Der Valk, Peter Reiss, Liesbeth Van Weert, Frank Van Leth, Victoria A Johnson, Jean-Pierre Sommadossi, Joep MA Lange
Publication date
2003/5/2
Journal
Aids
Volume
17
Issue
7
Pages
987-999
Publisher
LWW
Description
Objective:
To compare one protease inhibitor (PI)-based and two PI-sparing antiretroviral therapy regimens.
Methods:
International, open label, randomized study of antiretroviral drug-naive patients, with CD4 lymphocyte counts≥ 200× 10 6 cells/l and plasma HIV-1 RNA levels> 500 copies/ml. Treatment assignment to stavudine and didanosine plus indinavir or nevirapine or lamivudine. Primary study endpoint was the percentage of patients with plasma HIV-1 RNA levels< 500 copies/ml after 48 weeks in the intention-to-treat analysis (ITT).
Results:
In total, 298 patients were enrolled. After 48 weeks, the percentage of patients in the indinavir, nevirapine and lamivudine arms with HIV-1 RNA< 500 copies/ml was 57.0%, 58.4% and 58.7%, respectively, in an ITT analysis. After 96 weeks of follow-up, these percentages were 50.0%, 59.6% and 45.0%, respectively. The percentage of patients with HIV-1 RNA< 50 copies/ml …
Total citations
Scholar articles
R Van Leeuwen, C Katlama, RL Murphy, K Squires… - Aids, 2003